These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23264671)

  • 1. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
    Li JZ; Paredes R; Ribaudo HJ; Kozal MJ; Svarovskaia ES; Johnson JA; Geretti AM; Metzner KJ; Jakobsen MR; Hullsiek KH; Ostergaard L; Miller MD; Kuritzkes DR
    J Infect Dis; 2013 Mar; 207(6):893-7. PubMed ID: 23264671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
    Paredes R; Lalama CM; Ribaudo HJ; Schackman BR; Shikuma C; Giguel F; Meyer WA; Johnson VA; Fiscus SA; D'Aquila RT; Gulick RM; Kuritzkes DR;
    J Infect Dis; 2010 Mar; 201(5):662-71. PubMed ID: 20102271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
    Halvas EK; Wiegand A; Boltz VF; Kearney M; Nissley D; Wantman M; Hammer SM; Palmer S; Vaida F; Coffin JM; Mellors JW
    J Infect Dis; 2010 Mar; 201(5):672-80. PubMed ID: 20102272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
    Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Kozal MJ; Hullsiek KH; Miller MD; Bangsberg DR; Kuritzkes DR
    AIDS; 2012 Jan; 26(2):185-92. PubMed ID: 22179227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
    Higa N; Pelz A; Birch D; Beck IA; Sils T; Samson P; Bwakura-Dangarembizi M; Bolton-Moore C; Capparelli E; Chadwick E; Frenkel LM
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):261-264. PubMed ID: 31194860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Metzner KJ; Kozal MJ; Hullsiek KH; Balduin M; Jakobsen MR; Geretti AM; Thiebaut R; Ostergaard L; Masquelier B; Johnson JA; Miller MD; Kuritzkes DR
    JAMA; 2011 Apr; 305(13):1327-35. PubMed ID: 21467286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
    Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
    Lecossier D; Shulman NS; Morand-Joubert L; Shafer RW; Joly V; Zolopa AR; Clavel F; Hance AJ
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):37-42. PubMed ID: 15608522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
    Cozzi-Lepri A; Paredes ; Phillips AN; Clotet B; Kjaer J; Von Wyl V; Kronborg G; Castagna A; Bogner JR; Lundgren JD;
    HIV Med; 2012 Jan; 13(1):62-72. PubMed ID: 21848790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Geretti AM; Fox Z; Johnson JA; Booth C; Lipscomb J; Stuyver LJ; Tachedjian G; Baxter J; Touloumi G; Lehmann C; Owen A; Phillips A;
    PLoS One; 2013; 8(7):e69266. PubMed ID: 23874928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
    Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.